Back to Research Home
UTHRUnited Therapeutics Corporation
Health Care · Biotechnology: Pharmaceutical Preparations · Large
$587.50+0.46%
As of 23 Oct 2026Mkt cap $21.1B
Stage 13
WAIT
Fundamentals
—/75
Technical
7.4/15
Independent
—/90
GCAE viewFundamental evidence is unavailable, so the engine cannot approve ownership
Price
- 1M
- +24.4%
- 3M
- +11.3%
- 6M
- +3.6%
- 1Y
- +39.3%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 21.0xHist median 15.1x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 25.7x
- FCF yield
- 3.9%
Quality
- ROIC
- —
- Operating margin
- 47.9%
- FCF margin
- 32.7%
- Current ratio
- 6.6x
Growth
- Revenue growth
- +10.6%Latest FY YoY
- Revenue CAGR
- +17.2%
- EPS CAGR
- +29.0%
- FCF CAGR
- +21.5%
Capital
- Share-count trend
- −1.8%3Y annualised
- Net debt
- —
Annual trend
- CAGR 2021–2025
- +17.2%
- Latest · 2025
- $3B
- YoY
- +10.6%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental evidence is unavailable, so the engine cannot approve ownership
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-04
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded